( ), 1, 3
Sun, Richard L
Global GLP-1 Receptor Agonist Market (2026-32) Segmentation Analysis: The Global GLP-1 Receptor Agonist Market Report and Forecast 2026-2032 offers a detailed analysis of the market based on the following segments: Based on Product Type Semaglutide Ozempic Wegovy Rybelsus Others Liraglutide Victoza Saxenda Others Exenatide Dulaglutide Other (tirzepatide, etc.) Semaglutide has emerged as the leading product type in the Global GLP-1 Receptor Agonist Market because of its broad regulatory approvals, large-scale clinical impact, and exceptional adoption across major healthcare systems
Periodic body composition assessmentwhere feasiblemay therefore help contextualize total weight reduction relative to lean mass preservation
Breakthrough Therapy designation, if granted, would facilitate more frequent FDA interactions and potentially accelerate the review
Clinical and real-world evidence have demonstrated the potential of GLP-1RAs to reduce the risk of all-cause dementia and dementia due to AD in people with T2D [32, 34,35,36], and liraglutide has been shown to reduce neurodegeneration and the speed of decline in cognitive function in people with AD [29, 30]